{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T11:16:18Z","timestamp":1794914178227,"version":"4.9.1"},"reference-count":64,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"AstraZeneca BV","award":["ESR-19-20378"],"award-info":[{"award-number":["ESR-19-20378"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Heart failure with preserved ejection fraction (HFpEF) is characterized by increased diastolic left ventricular (LV) stiffness resulting from variable contributions of myocardial extracellular matrix (ECM) remodelling and titin-based cardiomyocyte stiffness. Sodium\u2013glucose cotransporter-2 inhibitors (SGLT2i) improved cardiomyocyte distensibility, inflammation, and oxidative stress in experimental and human HFpEF myocardium. We investigated whether dapagliflozin improves LV distensibility in phenotypically stratified HFpEF patients without significant myocardial fibrosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>STADIA-HFpEF was a 34-week, randomized, double-blind, placebo-controlled crossover trial. HFpEF patients underwent multi-level phenotypic stratification including cardiac magnetic resonance imaging to exclude structural cardiomyopathies and significant myocardial ECM remodelling. Participants were randomized to dapagliflozin 10\u2005mg or placebo for two 13-week treatment periods separated by an 8-week washout. The co-primary endpoints were changes in E\/e\u2032\/LV end-diastolic volume index (LVEDVi) and mean LV e\u2032, reflecting LV distensibility and relaxation. Secondary endpoints included echocardiographic variables, quality of life, 6-min walk distance, and inflammatory biomarkers. Between February 2020 and October 2022, 32 patients were randomized and 29 completed the study protocol. Median age was 73 (68\u201376) years including 28 women (88%). Dapagliflozin did not change E\/e\u2032\/LVEDVi compared with placebo 0.24 (0.20\u20130.32) to 0.26 (0.22\u20130.34) vs. 0.23 (0.22\u20130.29) to 0.25 (0.21\u20130.31); P = 0.370 nor did it change mean LV e\u2032 6.2 (5.6\u20137.5) to 6.2 (5.7\u20137.1) vs. 6.6 (5.6\u20137.4) to 6.7 (5.4\u20137.5); P = 0.448. Most secondary outcomes were neutral. However, an isolated improvement in LA conduit strain and numerical reductions in inflammatory biomarkers were observed during dapagliflozin treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In phenotypically stratified HFpEF patients without significant myocardial fibrosis, dapagliflozin did not improve LV distensibility or relaxation. An isolated improvement in LA conduit strain and numerical reductions in inflammatory biomarkers were observed; however, these exploratory findings require confirmation in larger studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvag091","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:49:08Z","timestamp":1791373748000},"source":"Crossref","is-referenced-by-count":0,"title":["Dapagliflozin in phenotypically stratified heart failure with preserved ejection fraction without myocardial fibrosis: the STADIA-HFpEF randomized crossover trial"],"prefix":"10.1093","author":[{"given":"Mari\u00eblle","family":"Scheffer","sequence":"first","affiliation":[{"name":"Department of Cardiology, OLVG , Oosterpark 9, Amsterdam 1091 AC ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1351-7178","authenticated-orcid":false,"given":"Willemijn","family":"van Maarschalkerwaart","sequence":"additional","affiliation":[{"name":"Department of Cardiology, OLVG , Oosterpark 9, Amsterdam 1091 AC ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7741-0142","authenticated-orcid":false,"given":"Chaohui","family":"Dong","sequence":"additional","affiliation":[{"name":"Ruhr-University Bochum, Medical Faculty, Institute of Physiology, Department of Cellular and Translational Physiology , Bochum D-44801 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7557-9489","authenticated-orcid":false,"given":"Jochem W D","family":"Landzaat","sequence":"additional","affiliation":[{"name":"Department of Cardiology, OLVG , Oosterpark 9, Amsterdam 1091 AC ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8552-0168","authenticated-orcid":false,"given":"Fanni","family":"Nedenyi","sequence":"additional","affiliation":[{"name":"Computational Medicine Core Group, Hungarian Centre of Excellence for Molecular Medicine (HCEMM) , Szeged H-6728 ,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin","family":"Delalat","sequence":"additional","affiliation":[{"name":"Ruhr-University Bochum, Medical Faculty, Institute of Physiology, Department of Cellular and Translational Physiology , Bochum D-44801 ,","place":["Germany"]},{"name":"Department of Physiology, Cardiovascular Research Institute Maastricht , Maastricht 6200 MD ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Innas","family":"Sultana","sequence":"additional","affiliation":[{"name":"Ruhr-University Bochum, Medical Faculty, Institute of Physiology, Department of Cellular and Translational Physiology , Bochum D-44801 ,","place":["Germany"]},{"name":"Department of Physiology, Cardiovascular Research Institute Maastricht , Maastricht 6200 MD ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3232-0995","authenticated-orcid":false,"given":"Oliver","family":"Jarkas","sequence":"additional","affiliation":[{"name":"Ruhr-University Bochum, Medical Faculty, Institute of Physiology, Department of Cellular and Translational Physiology , Bochum D-44801 ,","place":["Germany"]},{"name":"Department of Physiology, Cardiovascular Research Institute Maastricht , Maastricht 6200 MD ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gergely","family":"R\u00f6st","sequence":"additional","affiliation":[{"name":"Computational Medicine Core Group, Hungarian Centre of Excellence for Molecular Medicine (HCEMM) , Szeged H-6728 ,","place":["Hungary"]},{"name":"Bolyai Institute, University of Szeged , Szeged 6720 ,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annet","family":"Driessen-Waaijer","sequence":"additional","affiliation":[{"name":"Department of Radiology, OLVG , Amsterdam 1091 AC ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3053-0008","authenticated-orcid":false,"given":"Nazha","family":"Hamdani","sequence":"additional","affiliation":[{"name":"Ruhr-University Bochum, Medical Faculty, Institute of Physiology, Department of Cellular and Translational Physiology , Bochum D-44801 ,","place":["Germany"]},{"name":"Department of Physiology, Cardiovascular Research Institute Maastricht , Maastricht 6200 MD ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6718-2871","authenticated-orcid":false,"given":"Loek","family":"van Heerebeek","sequence":"additional","affiliation":[{"name":"Department of Cardiology, OLVG , Oosterpark 9, Amsterdam 1091 AC ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,17]]},"reference":[{"key":"2026111705222243300_pvag091-B1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","article-title":"Phenotype specific treatment of heart failure with preserved ejection fraction: a multiorgan road map","volume":"134","author":"Shah","year":"2016","journal-title":"Circulation"},{"key":"2026111705222243300_pvag091-B2","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","article-title":"Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes","volume":"70","author":"Shah","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026111705222243300_pvag091-B3","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction: JACC scientific statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026111705222243300_pvag091-B4","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"2026111705222243300_pvag091-B5","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1161\/CIRCRESAHA.121.318159","article-title":"From systemic inflammation to myocardial fibrosis: the heart failure with preserved ejection fraction paradigm revisited","volume":"128","author":"Paulus","year":"2021","journal-title":"Circ Res"},{"key":"2026111705222243300_pvag091-B6","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1161\/CIRCULATIONAHA.105.587519","article-title":"Myocardial structure and function differ in systolic and diastolic heart failure","volume":"113","author":"Van Heerebeek","year":"2006","journal-title":"Circulation"},{"key":"2026111705222243300_pvag091-B7","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1161\/CIRCULATIONAHA.111.076075","article-title":"Low myocardial protein kinase G activity in heart failure with preserved ejection fraction","volume":"126","author":"Van Heerebeek","year":"2012","journal-title":"Circulation"},{"key":"2026111705222243300_pvag091-B8","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1161\/CIRCRESAHA.114.301286","article-title":"Gigantic business: titin properties and function through thick and thin","volume":"114","author":"Linke","year":"2014","journal-title":"Circ Res"},{"key":"2026111705222243300_pvag091-B9","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1161\/CIRCULATIONAHA.114.013215","article-title":"Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin","volume":"131","author":"Zile","year":"2015","journal-title":"Circulation"},{"key":"2026111705222243300_pvag091-B10","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1161\/01.CIR.0000155257.33485.6D","article-title":"Cardiomyocyte stiffness in diastolic heart failure","volume":"111","author":"Borbely","year":"2005","journal-title":"Circulation"},{"key":"2026111705222243300_pvag091-B11","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1161\/CIRCULATIONAHA.114.009625","article-title":"Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction","volume":"131","author":"Mohammed","year":"2015","journal-title":"Circulation"},{"key":"2026111705222243300_pvag091-B12","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","article-title":"Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis","volume":"8","author":"Hahn","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026111705222243300_pvag091-B13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existing of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"2026111705222243300_pvag091-B14","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/ejhf.1902","article-title":"Characterization of the inflammatory-metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain the influence of sex on the evolution and potential treatment of the disease","volume":"22","author":"Packer","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026111705222243300_pvag091-B15","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1161\/CIRCULATIONAHA.120.045810","article-title":"Proteomic evaluation of the comorbidity-inflammation paradigm in heart failure with preserved ejection fraction: results from the Promis-HFpEF study","volume":"142","author":"Sanders-v Wijk","year":"2020","journal-title":"Circulation"},{"key":"2026111705222243300_pvag091-B16","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jchf.2015.10.007","article-title":"Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction","volume":"4","author":"Franssen","year":"2016","journal-title":"JACC Heart Fail"},{"key":"2026111705222243300_pvag091-B17","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026111705222243300_pvag091-B18","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026111705222243300_pvag091-B19","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1161\/CIRCULATIONAHA.123.065061","article-title":"Effect of dapagliflozin versus placebo on symptoms and 6-minute walk distance in patients with heart failure: the DETERMINE randomized clinical trials","volume":"149","author":"McMurray","year":"2024","journal-title":"Circulation"},{"key":"2026111705222243300_pvag091-B20","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/eurheartj\/ehaa943","article-title":"Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes","volume":"42","author":"Abraham","year":"2021","journal-title":"Eur Heart J"},{"key":"2026111705222243300_pvag091-B21","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial","volume":"27","author":"Nassif","year":"2021","journal-title":"Nat Med"},{"key":"2026111705222243300_pvag091-B22","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1093\/eurheartj\/ehae300","article-title":"Great debate: SGLT2 inhibitors should be first-line treatment in heart failure with reduced ejection fraction","volume":"45","author":"Packer","year":"2024","journal-title":"Eur Heart J"},{"key":"2026111705222243300_pvag091-B23","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/CIRCULATIONAHA.123.068089","article-title":"Nature and magnitude of the benefits of dapagliflozin and empagliflozin for heart failure","volume":"149","author":"Cleland","year":"2024","journal-title":"Circulation"},{"key":"2026111705222243300_pvag091-B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2026.107398","article-title":"Empagliflozin and functional aerobic capacity in individuals with increased risk of heart failure: the empire prevent cardiac trial","volume":"301","author":"Larsen","year":"2026","journal-title":"Am Heart J"},{"key":"2026111705222243300_pvag091-B25","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1002\/ejhf.1328","article-title":"Empagliflozin directly improves diastolic function in human heart failure","volume":"20","author":"Pabel","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026111705222243300_pvag091-B26","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/cvr\/cvaa123","article-title":"Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase G\u03b1 oxidation","volume":"117","author":"Kolijn","year":"2021","journal-title":"Cardiovasc Res"},{"key":"2026111705222243300_pvag091-B27","doi-asserted-by":"publisher","first-page":"4478","DOI":"10.1002\/ehf2.13055","article-title":"Stratified treatment of heart failure with preserved ejection fraction: rationale and design of the STADIA HFpEF trial","volume":"7","author":"Scheffer","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026111705222243300_pvag091-B28","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J Am Soc Echocardiogr"},{"key":"2026111705222243300_pvag091-B29","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","article-title":"A simple, evidence based approach to help guide diagnosis of heart failure with preserved ejection fraction","volume":"138","author":"Reddy","year":"2018","journal-title":"Circulation"},{"key":"2026111705222243300_pvag091-B30","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1161\/CIRCHEARTFAILURE.109.930701","article-title":"Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction","volume":"3","author":"Borlaug","year":"2010","journal-title":"Circ Heart Fail"},{"key":"2026111705222243300_pvag091-B31","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1161\/CIRCULATIONAHA.116.024822","article-title":"Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: a simultaneous invasive-echocardiographic study","volume":"135","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"2026111705222243300_pvag091-B32","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.jacc.2008.06.049","article-title":"Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping","volume":"52","author":"Iles","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026111705222243300_pvag091-B33","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.116.005277","article-title":"Interstitial fibrosis, functional status and outcomes in heart failure with preserved ejection fraction: insights from a prospective cardiac magnetic resonance imaging study","volume":"9","author":"Duca","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026111705222243300_pvag091-B34","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.echo.2025.03.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography and for heart failure with preserved ejection fraction diagnosis: an update from the American Society of Echocardiography","volume":"38","author":"Nagueh","year":"2025","journal-title":"J Am Soc Echocardiogr"},{"key":"2026111705222243300_pvag091-B35","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jacc.2013.10.055","article-title":"Left atrial size and function: role in prognosis","volume":"63","author":"Hoit","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026111705222243300_pvag091-B36","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.1464","article-title":"Left atrial strain and compliance in the diagnostic evaluation of heart failure with preserved ejection fraction","volume":"21","author":"Reddy","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026111705222243300_pvag091-B37","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12968-016-0308-4","article-title":"Cardiac T1 mapping and extracellular volume (ECV) in clinical practice: a comprehensive review","volume":"18","author":"Haaf","year":"2016","journal-title":"J Cardiovasc Magn Reson"},{"key":"2026111705222243300_pvag091-B38","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","author":"ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"2026111705222243300_pvag091-B39","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.2337\/dc16-1312","article-title":"Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG outcome trial?","volume":"39","author":"Verma","year":"2016","journal-title":"Diabetes Care"},{"key":"2026111705222243300_pvag091-B40","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2026111705222243300_pvag091-B41","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12933-026-03142-y","article-title":"Dapagliflozin-induced integrated improvements in left ventricular diastole, endothelial function, and arterial load: a randomized clinical trial","volume":"25","author":"Kimura-Medorima","year":"2026","journal-title":"Cardiovasc Diabetol"},{"key":"2026111705222243300_pvag091-B42","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11030867","article-title":"Natriuretic peptide levels and stages of left ventricular dysfunction in heart failure with preserved ejection fraction","volume":"11","author":"Dal Canto","year":"2023","journal-title":"Biomedicines"},{"key":"2026111705222243300_pvag091-B43","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jacbts.2019.04.003","article-title":"Cardiac microvascular endothelial enhancement of cardiomyocyte function is impaired by inflammation and restored by empagliflozin","volume":"4","author":"Juni","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"2026111705222243300_pvag091-B44","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/ejhf.1194","article-title":"Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial","volume":"20","author":"Ravassa","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026111705222243300_pvag091-B45","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/ejhf.3101","article-title":"Effects of empagliflozin on collagen biomarkers in patients with heart failure: findings from the EMPEROR trials","volume":"26","author":"Ferreira","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026111705222243300_pvag091-B46","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in heart failure: diuretic and cardiorenal effects","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation"},{"key":"2026111705222243300_pvag091-B47","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","article-title":"Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial","volume":"143","author":"Nassif","year":"2021","journal-title":"Circulation"},{"key":"2026111705222243300_pvag091-B48","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12933-018-0775-z","article-title":"Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure","volume":"17","author":"Soga","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"2026111705222243300_pvag091-B49","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.122.015176","article-title":"Empagliflozin improves left atrial strain in patients with type 2 diabetes: data from a randomized, placebo-controlled study","volume":"16","author":"Thiele","year":"2023","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026111705222243300_pvag091-B50","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.jacc.2019.01.059","article-title":"Left atrial structure and function and left ventricular diastolic dysfunction: JACC state-of-the-art review","volume":"73","author":"Thomas","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026111705222243300_pvag091-B51","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12933-023-01946-w","article-title":"Lack of durable natriuresis and objective decongestion following SGLT2 inhibition in randomized controlled trials of patients with heart failure","volume":"22","author":"Packer","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"2026111705222243300_pvag091-B52","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.jacc.2025.06.055","article-title":"The adipokine hypothesis of heart failure with a preserved ejection fraction: a novel framework to explain pathogenesis and guide treatment","volume":"86","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026111705222243300_pvag091-B53","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1161\/CIRCHEARTFAILURE.113.000539","article-title":"Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model","volume":"6","author":"Hamdani","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2026111705222243300_pvag091-B54","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13098-024-01325-9","article-title":"Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus","volume":"16","author":"Zhang","year":"2024","journal-title":"Diabetol Metab Syndr"},{"key":"2026111705222243300_pvag091-B55","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10081166","article-title":"Emergence of SGLT2 inhibitors as powerful antioxidants in human diseases","volume":"10","author":"Tsai","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"2026111705222243300_pvag091-B56","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s11897-021-00529-8","article-title":"SGLT2 inhibitors and their mode of action in heart failure\u2014has the mystery been unravelled?","volume":"18","author":"Pabel","year":"2021","journal-title":"Curr Heart Fail Rep"},{"key":"2026111705222243300_pvag091-B57","doi-asserted-by":"publisher","first-page":"5208","DOI":"10.1111\/dom.70727","article-title":"Exercise metabolic flexibility in type 2 diabetes treated with empagliflozin: an exploratory analysis of the randomised trial EMPA-HEART","volume":"28","author":"Nesti","year":"2026","journal-title":"Diab Obes Metab"},{"key":"2026111705222243300_pvag091-B58","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jchf.2018.06.008","article-title":"Heart failure with preserved ejection fraction expert panel report: current controversies and implications for clinical trials","volume":"6","author":"Parikh","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026111705222243300_pvag091-B59","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1161\/CIRCULATIONAHA.122.059755","article-title":"Effects of empagliflozin in women and men with heart failure and preserved ejection fraction","volume":"146","author":"Butler","year":"2022","journal-title":"Circulation"},{"key":"2026111705222243300_pvag091-B60","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.122.062832","article-title":"Sex differences in characteristics, outcomes and treatment response with dapagliflozin across the range of ejection fraction in patients with heart failure: insights from DAPA-HF and DELIVER","volume":"147","author":"Wang","year":"2023","journal-title":"Circulation"},{"key":"2026111705222243300_pvag091-B61","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.echo.2020.08.015","article-title":"Cardiac reserve and exercise capacity: insights from combined cardiopulmonary and exercise echocardiography stress testing","volume":"34","author":"Pugliese","year":"2021","journal-title":"J Am Soc Echocardgiogr"},{"key":"2026111705222243300_pvag091-B62","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12933-022-01618-1","article-title":"Effect of empagliflozin on left ventricular contractility and peak oxygen uptake in subjects with type 2 diabetes without heart disease: results of the EMPA-HEART trial","volume":"21","author":"Nesti","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"2026111705222243300_pvag091-B63","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"2026111705222243300_pvag091-B64","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The perindopril in elderly people with chronic heart failure (PEP-CHF) study","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvag091\/72066262\/pvag091.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvag091\/72066262\/pvag091.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T10:22:30Z","timestamp":1794910950000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article\/doi\/10.1093\/ehjcvp\/pvag091\/8935258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,17]]},"references-count":64,"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvag091","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,17]]},"article-number":"pvag091"}}